{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-019020","form_type":"8-K","ticker":"LUCD","cik":"0001799011","company_name":"Lucid Diagnostics Inc.","filed_at":"2024-05-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.166095+00:00","generated_at":"2026-06-02T01:06:10.697291+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lucid Diagnostics Q1 revenue $1.0M; net loss $18.1M; EsoGuard volume up 10% sequentially","bullets":["EsoGuard revenue $1.0M, flat vs Q4'23 but up 124% YoY.","GAAP net loss $18.1M ($0.40/share); non-GAAP adjusted loss $9.4M ($0.21/share).","Cash $24.8M at quarter end; subsequent $11.6M from Series B-1 offering.","MolDX pre-submission meeting scheduled July 17, 2024 for EsoGuard coverage.","EsoGuard test volume 2,420, +10% sequentially and +31% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-019020","json":"https://secwatch.observer/filing/0001493152-24-019020.json","markdown":"https://secwatch.observer/filing/0001493152-24-019020.md","text":"https://secwatch.observer/filing/0001493152-24-019020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/0001493152-24-019020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T01:06:10.697291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e6cb5d403109e8551fab21e87743adbc6378dd59","claim":"Lucid Diagnostics Inc. reported the three months ended March 31, 2024 results: revenue $1.0 million, net income $18.1 million or $(0.40) per common share, EPS $(0.40) per common share.","evidence_excerpt":"regional plans in biomarker legislation states and pilots with national plans. Financial Results ● For the three months ended March 31, 2024, EsoGuard related revenues were $1.0 million. Operating expenses were approximately $11.8 million, which included stock-based compensation expenses of $0.9 million. GAAP net loss attributable to common stockholders was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1799011/000149315224019020/0001493152-24-019020-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2024"},{"label":"Revenue","value":"$1.0 million"},{"label":"Net income","value":"$18.1 million or $(0.40) per common share"},{"label":"EPS","value":"$(0.40) per common share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}